Oneness Biotech Co., Ltd.

BDL:ONES Stock Report

Market Cap: US$1.3b

Oneness Biotech Past Earnings Performance

Past criteria checks 0/6

Oneness Biotech's earnings have been declining at an average annual rate of -29.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 27.6% per year.

Key information

-29.5%

Earnings growth rate

-23.9%

EPS growth rate

Pharmaceuticals Industry Growth21.0%
Revenue growth rate27.6%
Return on equity-9.5%
Net Margin-1,121.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Oneness Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BDL:ONES Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24112-1,259220980
30 Jun 24102-979198959
31 Mar 2490-1,141180965
31 Dec 2387-1,313177953
30 Sep 2376-1,469166952
30 Jun 2371-967172979
31 Mar 231,068-293176940
31 Dec 221,066360167919
30 Sep 221,0691,131168854
30 Jun 221,079679152791
31 Mar 2275-132133739
31 Dec 2166-403117806
30 Sep 2152-1,099105791
30 Jun 2130-901103695
31 Mar 214964107727
31 Dec 2042-242108589
30 Sep 2039156108518
30 Jun 204275100481
31 Mar 2013-48180335
31 Dec 1913-32270239
30 Sep 1916-20245170
30 Jun 1915-25540134
31 Mar 1916-20942108
31 Dec 1819-2354694
30 Sep 1815-2307068
30 Jun 1812-1517355
31 Mar 1810-1717658
31 Dec 173-1557565
30 Sep 173-1497070
30 Jun 174-346370
31 Mar 175-215871
31 Dec 166-145363
30 Sep 166-55357
30 Jun 165-1064855
31 Mar 169-1034653
31 Dec 158-934754
30 Sep 157-275467
30 Jun 1581725971
31 Mar 1551956460
31 Dec 1452006061
30 Sep 1451185564
30 Jun 1441165261
31 Mar 1442364673
31 Dec 1352764675

Quality Earnings: ONES is currently unprofitable.

Growing Profit Margin: ONES is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ONES is unprofitable, and losses have increased over the past 5 years at a rate of 29.5% per year.

Accelerating Growth: Unable to compare ONES's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ONES is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).

Return on Equity

High ROE: ONES has a negative Return on Equity (-9.46%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 05:20
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oneness Biotech Co., Ltd. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yenya KuoCapital Securities Corporation
Jianzheng WuCapital Securities Corporation
Regina LeeJih Sun Securities Investment Consulting Co., Ltd.